Results 81 to 90 of about 5,951 (176)

Quantitative and Clinical Pharmacology Perspectives on Next‐Generation Malaria Prevention Using Vaccines and Long‐Acting Monoclonal Antibodies

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Malaria remains a significant global health burden, particularly among pediatric populations in endemic regions. Recent advances in preventive interventions highlight the complementary roles of vaccines and long‐acting monoclonal antibodies (mAbs) in reducing infection risk.
Sabiha R. Mim, Leonardo C. Xavier, Francine J. Azeredo, Sihem Ait‐Oudhia   +3 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Modeling of Elexacaftor/Tezacaftor/Ivacaftor in Infants With Cystic Fibrosis. [PDF]

CPT Pharmacometrics Syst Pharmacol
Truong NH, Benaboud S, Bouazza N, Deneuville E, Mornand A, Reix P, Ribault M, Burgel PR, Froelicher-Bournaud L, Rouillon S, Sanoufi MR, Lui G, Urien S, Tréluyer JM, Sermet-Gaudelus I, Foissac F, Modul‐CF study group.   +16 more
europepmc   +1 more source

Risk Assessment Models for Heated Tobacco Products

Risk Analysis, Volume 46, Issue 8, August 2026.
ABSTRACT Heated tobacco products (HTPs) are marketed as alternatives to conventional cigarettes with a potential reduced risk profile. Yet, their actual impact on cancer and noncancer disease risk remains uncertain and requires rigorous quantitative assessment.
Lucia Maddalena, Beril Yildiz, Francesca Del Vecchio Blanco, Mario Rosario Guarracino   +3 more
wiley   +1 more source

Model-informed dose optimization of carvedilol and nebivolol in cirrhotic patients: a pilot randomized clinical study. [PDF]

Sci Rep
Tarek M, Ali AA, Biomy R, Abdelkawy K, El-Khateeb E.   +4 more
europepmc   +1 more source

Model-informed safety management of tocilizumab for pediatric sJIA: a PBPK approach for dose-escalation and vaccination timing. [PDF]

Front Immunol
Yang Y, Wang R, Li Z, Zheng L, Shen C.
europepmc   +1 more source

Development of an adult whole-body PBPK model of irinotecan and its metabolites for predicting UGT1A1/CYP3A-mediated drug-drug interactions. [PDF]

Front Pharmacol
Chen B, Li L, Xu W, Xu H, Zhu X, He Q, Zhu X, Chi-Lui Ho P, Xiang X, Ji P.   +9 more
europepmc   +1 more source

Leveraging [¹⁸F]F-Piflufolastat PET for PBPK Prediction of Tissue Distribution and Therapy Optimization in Prostate Cancer. [PDF]

Clin Transl Sci
van der Gaag S, Veerman MJC, Yilmaz H, Amsu J, Pruijn SJV, Oprea-Lager DE, Cysouw MCF, Jansen BHE, Yaqub MM, Vis AN, Hendrikse H, Bartelink IH.   +11 more
europepmc   +1 more source

Midazolam Dosing During CRRT: A Combined Ex Vivo and Physiologically-Based Pharmacokinetic Approach. [PDF]

CPT Pharmacometrics Syst Pharmacol
McKnite AM, Hamadeh A, Hunt JP, Green DJ, Imburgia C, Whelan A, Hudson R, Chevalier A, Mathis CL, Yang MJ, Dwyer JP, Edginton A, Watt KM.   +12 more
europepmc   +1 more source

PBPK modeling predicts rilzabrutinib dose adjustments using BTK occupancy for CYP3A4 interactions and hepatic impairment. [PDF]

Sci Rep
Yan X, Yan Z, Xiao L, Lu D.
europepmc   +1 more source

Physiologically based pharmacokinetic modeling and dose adjustment of imipenem in pediatric patients with renal impairment. [PDF]

Front Cell Infect Microbiol
Feng C, Xiao P, Qu Y, Fan K, Wang Y, Zhang X, Wang X, Pan J, Deng Y, Yu Y.   +9 more
europepmc   +1 more source